Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7369176 | 0.84 | QDPR (0.72) | QDPR | |
| SCHEMBL14923997 | 0.81 | QDPR (0.64) | QDPR | |
| SCHEMBL8266073 | 0.81 | QDPR (0.56) | QDPR | |
| SCHEMBL13898494 | 0.81 | QDPR (0.68) | QDPR | |
| SCHEMBL155267 | 0.81 | QDPR (0.68) | QDPR | |
| SCHEMBL6043136 | 0.81 | QDPR (0.68) | QDPR | |
| SCHEMBL8382616 | 0.81 | QDPR (1.00) | QDPR | |
| SCHEMBL578138 | 0.81 | QDPR (0.68) | QDPR | |
| SCHEMBL13917870 | 0.80 | QDPR (0.62) | QDPR | |
| SCHEMBL16862164 | 0.80 | QDPR (0.67) | QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3741749-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3738960-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-2585470-B1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO LTD (KR) | 2017-01-25 | — | — | EP | disclosed |
| EP-2017278-B1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD KK (JP) | 2016-11-02 | — | — | EP | disclosed |
| EP-2975042-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | Boehringer Ingelheim International GmbH (DE) | 2016-01-20 | — | — | EP | disclosed |
| EP-2961750-A1 | SUBSTITUTED 7-OXO-PYRIDO [2, 3-D]PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF EGFR / ERBB2 RELATED DISORDERS | Amgen Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | MSD KK (JP) | 2014-10-09 | — | — | US | disclosed |
| WO-2014134308-A1 | SUBSTITUTED 7-OXO-PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF EGFR / ERBB2 RELATED DISORDERS | AMGEN INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014134308-A1 | SUBSTITUTED 7-OXO-PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF EGFR / ERBB2 RELATED DISORDERS | AMGEN INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | SAGARA TAKESHI | 2011-08-04 | — | — | US | disclosed |
| US-7935708-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2011-05-03 | — | — | US | disclosed |
| WO-2011009097-A2 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| US-7834019-B2 | Substituted pyrazolo[3,4-d]pyrimidinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | MERCK SHARP & DOHME LLC | 2010-03-11 | — | — | US | disclosed |
| US-7504400-B2 | for the treatment of atherosclerosis, pancreatitis, obesity, hyper-triglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and type II diabetes; apolipoprotein B secretion inhibitors also for lipid lowering activity; compounds can selectively block MTP at the level of the gut wall in mammals | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-17 | — | — | US | disclosed |
| EP-2017278-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070191383-A1 | Mtp inhibiting aryl piperydines or piperazines substituted with 5-membered heterocycles | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | QDPR 2321/4885 |
| US-20070191383-A1 | Mtp inhibiting aryl piperydines or piperazines substituted with 5-membered heterocycles | APOB, PNLIP, LPL | QDPR 374/4885 |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | WEE1, WEE2, GRK3 | QDPR 2321/4885 |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | QDPR 1566/4885 |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | WEE1, WEE2, GRK3 | QDPR 2321/4885 |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | QDPR 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.